A phase II study of risk-adapted intravenous melphalan in patients with AL amyloidosis

British Journal of Haematology

Volumn 157, Issue 6, 2012, Pages 766-769

  Mollee, Peter ^a,b   Tiley, Campbell ^c   Cunningham, Ilona ^d   Moore, John ^e   Prince, H Miles ^f   Cannell, Paul ^g   Gibbons, Steve ^h   Tate, Jill ⁱ   Paul, Sanjoy ^b   Mar Fan, Helen ^a,b   Gill, Devinder S ^a  

^a PRINCESS ALEXANDRA HOSPITAL   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c GOSFORD HOSPITAL   (Australia)

^d Department of Geriatric Medicine   (Australia)

^e ST VINCENT S HOSPITAL   (Australia)

^f PETER MACCALLUM CANCER CENTRE   (Australia)

^g ROYAL PERTH HOSPITAL   (Australia)

^h CHRISTCHURCH HOSPITAL   (New Zealand)

ⁱ Pathology Queensland ^*  (Australia)

Author keywords

AL amyloidosis; Autologous stem cell transplantation; Brain natriuretic peptide; Intravenous melphalan; Toxicity

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; DEXAMETHASONE; MELPHALAN;

ADULT; AGED; AMYLOIDOSIS; AUTOLOGOUS STEM CELL TRANSPLANTATION; BLOOD TOXICITY; BONE MARROW TOXICITY; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG INTERMITTENT THERAPY; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HUMAN; LETTER; LIGHT CHAIN; MALE; NEUTROPENIA; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; RISK FACTOR; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; AMYLOIDOSIS; ANTINEOPLASTIC AGENTS, ALKYLATING; FEMALE; HUMANS; MELPHALAN; MIDDLE AGED;

EID: 84863404118     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2012.09080.x     Document Type: Letter

References (10)

1. Bosanquet, A.G. & Gilby, E.D. (1984) Comparison of the fed and fasting states on the absorption of melphalan in multiple myeloma. Cancer Chemotherapy and Pharmacology, 12, 183-186.
2. Dietrich, S., Schonland, S.O., Benner, A., Bochtler, T., Kristen, A.V., Beimler, J., Hund, E., Zorn, M., Goldschmidt, H., Ho, A.D. & Hegenbart, U. (2010) Treatment with intravenous melphalan and dexamethasone is not able to overcome the poor prognosis of patients with newly diagnosed systemic light chain amyloidosis and severe cardiac involvement. Blood, 116, 522-528.
3. Dispenzieri, A., Gertz, M.A., Kyle, R.A., Lacy, M.Q., Burritt, M.F., Therneau, T.M., McConnell, J.P., Litzow, M.R., Gastineau, D.A., Tefferi, A., Inwards, D.J., Micallef, I.N., Ansell, S.M., Porrata, L.F., Elliott, M.A., Hogan, W.J., Rajkumar, S.V., Fonseca, R., Greipp, P.R., Witzig, T.E., Lust, J.A., Zeldenrust, S.R., Snow, D.S., Hayman, S.R., McGregor, C.G. & Jaffe, A.S. (2004a) Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood, 104, 1881-1887.
4. Dispenzieri, A., Gertz, M.A., Kyle, R.A., Lacy, M.Q., Burritt, M.F., Therneau, T.M., Greipp, P.R., Witzig, T.E., Lust, J.A., Rajkumar, S.V., Fonseca, R., Zeldenrust, S.R., McGregor, C.G. & Jaffe, A.S. (2004b) Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. Journal of Clinical Oncology, 22, 3751-3757.
5. Gertz, M., Lacy, M., Dispenzieri, A., Hayman, S., Kumar, S., Buadi, F., Leung, N. & Litzow, M. (2008) Troponin T level as an exclusion criterion for stem cell transplantation in light-chain amyloidosis. Leukaemia & Lymphoma, 49, 36-41.
6. Jimenez-Zepeda, V.H., Franke, N., Delgado, D., Winter, A., Stewart, K., Mikhael, J., Reece, D., Trudel, S., Chen, C. & Kukreti, V. (2010) High-Dose Melphalan for AL Amyloidosis: the Importance of Case Selection to Improve Clinical Outcomes. Blood, 116, 996. Abstract 2403.
7. Lachmann, H.J., Gallimore, R., Gillmore, J.D., Carr-Smith, H.D., Bradwell, A.R., Pepys, M.B. & Hawkins, P.N. (2003) Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy. British Journal of Haematology, 122, 78-84.
8. Mollee, P., Marlton, P., Mills, A., Bird, R. & Gill, D. (2005) Unexpected hematologic toxicity associated with the use of intravenous intermediate dose melphalan and dexamethasone in patients with cardiac AL amyloidosis. Haematologica, 90, 202. Abstract PO.1409.
9. Sattianayagam, P., Hawkins, P. & Gillmore, J. (2009) Amyloid and the GI tract. Expert Review of Gastroenterology & Hepatology, 3, 615-630.
10. Schey, S.A., Kazmi, M., Ireland, R. & Lakhani, A. (1998) The use of intravenous intermediate dose melphalan and dexamethasone as induction treatment in the management of de novo multiple myeloma. European Journal of Haematology, 61, 306-310.